Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Clin Pract ; 2022: 4836731, 2022.
Article in English | MEDLINE | ID: mdl-35685610

ABSTRACT

Method: In this double-blind, randomized, placebo-controlled trial, 75 children (aged 6-12) diagnosed with ADHD were randomly assigned into two groups. The supplementation group received vitamin D3 (2000 IU), and the control group received a placebo for 3 months. Blood samples were collected at baseline and after intervention to analyze the 25(OH)D, paraxonase-1 activity (PON-1), Total Antioxidant Capacity (TAC), and 8-isoprostan levels. Results: A significant rise in circulating 25(OH)D was observed in the vitamin D group versus the placebo group at the end of the study. There was no reduction in 8-isoprostan levels in the vitamin D group compared to the placebo group. Serum paraxonase-1 and TAC concentration decreased in both groups, but these alterations were not statistically significant in the treatment group versus the placebo group at the end of the intervention. Conclusion: Vitamin D supplementation for 3 months did not have beneficial effects on biomarkers of oxidative stress status. To confirm these findings, further studies on children are suggested.


Subject(s)
Attention Deficit Disorder with Hyperactivity , Vitamin D , Antioxidants/therapeutic use , Attention Deficit Disorder with Hyperactivity/drug therapy , Child , Dietary Supplements , Humans , Vitamin D/therapeutic use , Vitamins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...